FCM (Flow Cytometry)
(Overlay Peak curve showing Jurkat cells stained with AAA28074 (red line) at 1:50. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.)
GFAP recombinant antibody
GFAP Recombinant Monoclonal Antibody
IHC: 1:20-1:200
IF: 1:20-1:200
FC/FACS: 1:20-1:200
FCM (Flow Cytometry)
(Overlay Peak curve showing Jurkat cells stained with AAA28074 (red line) at 1:50. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.)
FCM (Flow Cytometry)
(Overlay Peak curve showing Jurkat cells stained with AAA28074 (red line) at 1:50. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.)
IF (Immunofluorescence)
(Immunofluorescence staining of U87 cell with AAA28074 at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).)
IF (Immunofluorescence)
(Immunofluorescence staining of U87 cell with AAA28074 at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).)
IF (Immunofluorescence)
(Immunofluorescence staining of SH-SY5Y cell with AAA28074 at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).)
IF (Immunofluorescence)
(Immunofluorescence staining of SH-SY5Y cell with AAA28074 at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).)
IHC (Immunohistochemistry)
(IHC image of AAA28074 diluted at 1:300 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.)
IHC (Immunohistochemistry)
(IHC image of AAA28074 diluted at 1:300 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.)
IHC (Immunohistochemistry)
(IHC image of AAA28074 diluted at 1:300 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.)
IHC (Immunohistochemistry)
(IHC image of AAA28074 diluted at 1:300 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Mouse IgG labeled by HRP and visualized using 0.05% DAB.)
WB (Western Blot)
(Western BlotPositive WB detected in: MCF7 whole cell lysate, Mouse Brain tissue lysate, Rat Brain tissue lysateAll lanes: GFAP antibody at 1:1000SecondaryGoat polyclonal to mouse IgG at 1/50000 dilutionPredicted band size: 50 kDaObserved band size: 55 kDa)
WB (Western Blot)
(Western BlotPositive WB detected in: MCF7 whole cell lysate, Mouse Brain tissue lysate, Rat Brain tissue lysateAll lanes: GFAP antibody at 1:1000SecondaryGoat polyclonal to mouse IgG at 1/50000 dilutionPredicted band size: 50 kDaObserved band size: 55 kDa)
NCBI and Uniprot Product Information
Similar Products
Product Notes
The GFAP gfap (Catalog #AAA28074) is a Recombinant Antibody produced from HEK293F Cell and is intended for research purposes only. The product is available for immediate purchase. The GFAP Recombinant Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's GFAP can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FC/FACS). WB: 1:1000-1:5000 IHC: 1:20-1:200 IF: 1:20-1:200 FC/FACS: 1:20-1:200. Researchers should empirically determine the suitability of the GFAP gfap for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "GFAP, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.